Cerus Corp (CERS)
3.25
-0.09 (-2.69%)
USD |
NASDAQ |
Feb 03, 16:00
3.25
0.00 (0.00%)
After-Hours: 19:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 576.62M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -35.52% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.612 |
| Price to Book Value | 7.886 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.9537 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 68.22% |
News
Headline
Wire
Time (ET)
MT Newswires
01/09 10:12
Yahoo
01/09 08:30
Yahoo
12/21 05:50
Yahoo
11/09 05:58
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/27/2023* | -- | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/27/2023* | -- | Results | Q4 2022 | -- | -0.05 | -- | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.05 | -0.05 | 0.00% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.06 | -0.06 | 5.26% | |
| 05/05/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.07 | -0.08 | 16.00% |
*Estimated Date/Time
Earnings
Profile
Edit
| Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. |
| URL | http://www.cerus.com |
| Investor Relations URL | https://ir.cerus.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
| Revenue (TTM) | 157.88M |
| Total Expenses (TTM) | 188.97M |
| Net Income (TTM) | -38.27M |
| Total Assets (Quarterly) | 215.40M |
| Total Liabilities (Quarterly) | 141.33M |
| Shareholders Equity (Quarterly) | 73.12M |
| Cash from Operations (TTM) | -25.08M |
| Cash from Investing (TTM) | -39.21M |
| Cash from Financing (TTM) | 15.83M |
Ratings
Profile
Edit
| Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. |
| URL | http://www.cerus.com |
| Investor Relations URL | https://ir.cerus.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CERS Tweets |